Costs associated with follicular lymphoma among individuals diagnosed with non-Hodgkin lymphoma: a longitudinal analysis using SEER-Medicare data
| Autor: | Husam Albarmawi, Aakash Bipin Gandhi, Sreevalsa Appukkuttan, Eberechukwu Onukwugha, Kai Sun, Madhuram Nagarajan, Mecide Gharibo, Jean Yared, Avin Yaldo, Karen Keating |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Follicular lymphoma Seer medicare Medicare Cost burden 03 medical and health sciences 0302 clinical medicine immune system diseases hemic and lymphatic diseases Internal medicine medicine Humans Lymphoma Follicular Aged business.industry Lymphoma Non-Hodgkin Hematology medicine.disease United States Lymphoma 030220 oncology & carcinogenesis Costs and Cost Analysis Hodgkin lymphoma business 030215 immunology |
| Zdroj: | Leukemialymphoma. 61(1) |
| ISSN: | 1029-2403 |
| Popis: | There is limited information on the cost burden associated with follicular lymphoma (FL) and how it compares to other non-Hodgkin lymphoma (NHL) subtypes. We examined the direct medical costs associated with FL and estimated the incremental 3-year cost of FL compared to other NHL subtypes. Using the linked Surveillance, Epidemiology and End Results-Medicare dataset, we identified 16,691 NHL patients aged 66 years or older who were diagnosed with NHL between 2007 and 2013. The mean 3-year cost among the full NHL sample was $120,120 (standard error (SE) 839). The mean 3-year cost per patient was $114,443 (SE 1738) for FL and $121,402 (SE 950) for non-FL subtypes. The incremental 3-year cost of FL compared to non-FL was US$-5458 (95% confidence interval: US$-9325 to US$-1590). Longitudinally, FL was less costly than other NHL subtypes in the first year only, and became more expensive in the second and third years. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|